Dr Brenda B Bell, MD | |
995 9th Avenue, Bessemer, AL 35021 | |
(205) 481-7155 | |
Not Available |
Full Name | Dr Brenda B Bell |
---|---|
Gender | Female |
Speciality | Radiology - Diagnostic Radiology |
Location | 995 9th Avenue, Bessemer, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1760487730 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0202X | Radiology - Diagnostic Radiology | 00004182 (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Brenda B Bell, MD 2000a Southbridge Pkwy, Ste 300, Birmingham, AL 35209-7718 Ph: (205) 871-4274 | Dr Brenda B Bell, MD 995 9th Avenue, Bessemer, AL 35021 Ph: (205) 481-7155 |
News Archive
A clinical trial designed to replace the genetic defect causing the most common form of muscular dystrophy has uncovered an unexpected aspect of the disease. The trial, based on therapy designed by scientists at the University of North Carolina at Chapel Hill School of Medicine, showed that some patients mount an immune response to the dystrophin protein even before they have received the gene therapy.
Advanced Biological Laboratories (ABL) S.A., a biomedical company engaged in the development and commercialization of personalized healthcare electronic medical record systems coupled with expert rules using decision support tools, is pleased to announce today that the Canadian Intellectual Property Office has issued a Notice of Allowance and the Patent Office of India has issued a new patent for our patent applications derived from our U.S. Patent Nos. 6,081,786 and 6,188,988 to Barry et al.
Chicken pox, the childhood affliction of earlier generations, has been largely neutralized by the varicella vaccine, according to a new study by the Kaiser Permanente Vaccine Study Center, which appears in the current online issue of Pediatrics.
EKF Diagnostics Holdings plc, the AIM listed point-of-care business, announces that it has received an initial order worth £3 m from a partner from the private sector to supply PrimeStore MTM, a novel patented sample collection device, to be used in a COVID-19 testing programme for UK staff.
› Verified 8 days ago